Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 3/20 | 0.39 |
| ▸ | BMPR1B | O00238 | 1/20 | 0.34 |
| ▸ | BMPR1A | P36894 | 1/20 | 0.34 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.34 |
| ▸ | ACVRL1 | P37023 | 1/20 | 0.34 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.33 |
| ▸ | HPGD | P15428 | 2/20 | 0.33 |
| ▸ | HTR5A | P47898 | 1/20 | 0.33 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.33 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4505225 | 0.88 | HSP90AA1 (0.39) | HSD11B1BMPR1BBMPR1ATGFBR1ACVRL1 | |
| SCHEMBL4513450 | 0.83 | HSD11B1 (0.48) | HSD11B1HPGD | |
| SCHEMBL13674485 | 0.82 | OPRM1 (0.39) | HSD11B1P2RX7ALDH1A1 | |
| SCHEMBL4510197 | 0.82 | OPRM1 (0.39) | HSD11B1P2RX7ALDH1A1 | |
| SCHEMBL4509399 | 0.81 | MCL1 (0.39) | HSD11B1BMPR1BBMPR1ATGFBR1ACVRL1 | |
| SCHEMBL4514955 | 0.81 | S1PR1 (0.40) | HSD11B1BMPR1BBMPR1ATGFBR1ACVRL1 | |
| SCHEMBL14365295 | 0.81 | PPARA (0.37) | HSD11B1HPGDHSP90AA1HSP90AB1ALDH1A1 | |
| SCHEMBL13674552 | 0.81 | ACVRL1 (0.36) | HSD11B1BMPR1BBMPR1ATGFBR1ACVRL1 | |
| SCHEMBL4506045 | 0.80 | HRH3 (0.39) | HSD11B1 | |
| SCHEMBL4512718 | 0.80 | ALDH1A1 (0.36) | HSD11B1BMPR1BBMPR1ATGFBR1ACVRL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090264650-A1 | Prophylactic/Therapeutic Agent for Diabetes | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-10-22 | — | — | US | disclosed |
| US-20090264650-A1 | Prophylactic/Therapeutic Agent for Diabetes | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-10-22 | — | — | US | disclosed |
| US-20090264650-A1 | Prophylactic/Therapeutic Agent for Diabetes | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-10-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264650-A1 | Prophylactic/Therapeutic Agent for Diabetes | HSD11B1, HSD17B1, HSD11B2 | HSD11B1 1/4885BMPR1B 3003/4885BMPR1A 2912/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.